# GSK plc: financial statements, quarterly

GSK · NYSE · CIK 1131399 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/gsk.md) · [Financials](/companies/gsk/financials.md) · [Filings](/companies/gsk/filings.md) · [Insiders](/companies/gsk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gsk/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2014-12-31) | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | [5.8](/filings/0001193125-18-088407.md) | [4.9](/filings/0001193125-19-076716.md) | [3.8](/filings/0001193125-20-065064.md) | [3.9](/filings/0001193125-21-079417.md) | [4.7](/filings/0001193125-22-068957.md) | [6.3](/filings/0001193125-23-067105.md) | [4.3](/filings/0001131399-24-000007.md) | [3.7](/filings/0001131399-25-000007.md) | [2.9](/filings/0001131399-26-000004.md) | [3.9](/filings/0001131399-26-000004.md) | [3.4](/filings/0001131399-26-000004.md) |
| Current assets | $bn | not reported | not reported | [16.7](/filings/0001193125-18-088407.md) | [15.9](/filings/0001193125-19-076716.md) | [16.9](/filings/0001193125-20-065064.md) | [19.5](/filings/0001193125-21-079417.md) | [20.2](/filings/0001193125-22-068957.md) | [18.7](/filings/0001193125-23-067105.md) | [20.8](/filings/0001131399-24-000007.md) | [18.6](/filings/0001131399-25-000007.md) | [17.0](/filings/0001131399-26-000004.md) | [17.5](/filings/0001131399-26-000004.md) |
| Total assets | $bn | not reported | not reported | [59.1](/filings/0001193125-18-088407.md) | [56.4](/filings/0001193125-19-076716.md) | [58.1](/filings/0001193125-20-065064.md) | [79.7](/filings/0001193125-21-079417.md) | [80.4](/filings/0001193125-22-068957.md) | [79.1](/filings/0001193125-23-067105.md) | [60.1](/filings/0001131399-24-000007.md) | [59.0](/filings/0001131399-25-000007.md) | [59.5](/filings/0001131399-26-000004.md) | [61.1](/filings/0001131399-26-000004.md) |
| Current liabilities | $bn | not reported | not reported | [19.0](/filings/0001193125-18-088407.md) | [26.6](/filings/0001193125-19-076716.md) | [22.5](/filings/0001193125-20-065064.md) | [24.1](/filings/0001193125-21-079417.md) | [22.1](/filings/0001193125-22-068957.md) | [23.7](/filings/0001193125-23-067105.md) | [22.8](/filings/0001131399-24-000007.md) | [21.1](/filings/0001131399-25-000007.md) | [21.7](/filings/0001131399-26-000004.md) | [21.4](/filings/0001131399-26-000004.md) |
| Total liabilities | $bn | not reported | not reported | [54.1](/filings/0001193125-18-088407.md) | [52.9](/filings/0001193125-19-076716.md) | [54.4](/filings/0001193125-20-065064.md) | [61.3](/filings/0001193125-21-079417.md) | [59.6](/filings/0001193125-22-068957.md) | [57.8](/filings/0001193125-23-067105.md) | [50.1](/filings/0001131399-24-000007.md) | [46.2](/filings/0001131399-25-000007.md) | [46.4](/filings/0001131399-26-000004.md) | [45.2](/filings/0001131399-26-000004.md) |
| Shareholders' equity | $bn | [4.9](/filings/0001193125-18-088407.md) | [8.9](/filings/0001193125-19-076716.md) | [1.1](/filings/0001193125-18-088407.md) | [(0.1)](/filings/0001193125-19-076716.md) | [3.8](/filings/0001193125-20-065064.md) | [11.4](/filings/0001193125-21-079417.md) | [14.6](/filings/0001193125-22-068957.md) | [15.1](/filings/0001193125-23-067105.md) | [10.6](/filings/0001131399-24-000007.md) | [13.3](/filings/0001131399-25-000007.md) | [13.7](/filings/0001131399-26-000004.md) | [16.4](/filings/0001131399-26-000004.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 4,315,445,026 at 2025-12-31, from the cover of the [20-F filed 2026-03-06](/filings/0001131399-26-000004.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.